Sitomegalovirus (CMV) ga qarshi antitanalar, sifatli, IgM
Kod:17006|CPT:86645|LOINC:24119-0
| Kabi | Sitomegalovirus (CMV) ga qarshi antitana, IgM |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Kimyoluminessent immunoanaliz (CLIA)
- Ferment immunoanalizi (EIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Avoid smoking for 30 minutes before the blood draw.
- If submitting acute and convalescent samples, send each specimen with a separate requisition.
Qanday foydalanish
CMV IgM antitana testi (CMV IgM; sitomegalovirusning immediate early oqsiliga qarshi antitana) hozirgi yoki yaqinda o‘tgan CMV infeksiyasini tashxislashda yordam beradi. CMV IgM infeksiyadan keyin 12 oydan ortiq saqlanishi va ikkilamchi infeksiya yoki reaktivatsiya bilan ham mavjud bo‘lishi mumkinligi sababli, yakkalangan IgM reaktivligi birlamchi infeksiyani tasdiqlamaydi. Juft namunalar bo‘yicha IgG serokonversiyasi birlamchi infeksiya uchun eng kuchli serologik dalilni beradi. Kutilayotgan o‘tkir kasallikda CMV IgG va IgM bo‘yicha juft tekshiruvlar ikki yoki undan ortiq haftalik interval bilan tavsiya etiladi, va nuklein kislota amplifikatsiyasi testi faol infeksiyani aniqlashi mumkin. Ushbu testni buyurtma qilish immuniteti susaygan bemorlarda (masalan, OIV infeksiyasi, o‘sma yoki immunsupressiv terapiya), homiladorlikda onadagi birlamchi infeksiya xavfini ko‘rib chiqishda, hamda ehtimoliy tug‘ma CMV infeksiyasining diagnostik tekshiruvlarida maqsadga muvofiq.
Cheklovlar
CMV infeksiyasi butun dunyoda keng tarqalgan; birlamchi infeksiyadan so‘ng virus latent holatga o‘tadi, va immun nazoratning yo‘qolishi reaktivatsiyaga imkon beradi, bu immuniteti susaygan bemorlarda klinik jihatdan ahamiyatli kasallikka olib kelishi mumkin. Yuqtirish tana suyuqliklari bilan yaqin kontakt, jinsiy yo‘l, yo‘ldosh orqali (transplatsentar) va transfuziya orqali sodir bo‘ladi. Immunokompetent shaxslarda ko‘pincha simptomlar bo‘lmaydi yoki mononuklyozga o‘xshash kasallik rivojlanadi, immuniteti buzilgan bemorlarda esa pnevmoniya yoki gepatit kabi a’zolarga invaziv kasallik kuzatilishi mumkin. Homiladorlikning boshida onadagi birlamchi infeksiya homila infeksiyasi va noxush oqibatlar bilan bog‘liq. CMV-ga xos IgM infeksiyadan so‘ng erta paydo bo‘ladi va reaktivatsiya davrida ham mavjud bo‘lishi mumkin; sifatli ijobiy natijalar tahlilning kesish qiymatidan oshishni aks ettiradi va antitana kontsentratsiyasiga proportsional emas.
| O'lchov birligi | qualitative | ||||
|---|---|---|---|---|---|
| Referens oraliq |
| ||||
| Ko'rsatmalar | Clinical concern for CMV infection., Assessment of infectious complications in immunocompromised patients, including those with HIV infection, malignancy, or receiving immunosuppressive therapy., Maternal testing during pregnancy when acute CMV infection is suspected., Workup of suspected congenital CMV infection. |
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 0.5 mL (min 0.2 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Gaytant MA, Steegers EAP, Semmekrot BA, Merkus HMMW, Galama JMD. Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet Gynecol Surv. 2002;57:245-256.
Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus and newborn infant. Clin Microbiol Rev. 2002;15:680-715.
Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol. 2001;54:84-88.
Brodeur BR, Lussier M, et al. New monoclonal antibodies for the detection of immediate early antigens of cytomegalovirus. Viral Immunology. 1992;5(1).
van Zanten J, van der Giessen M, et al. Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection. Clin Exp Immunol. 1991;83(1):102-107.
Shiraki K, Ishibashi M, et al. Antibody response to the immediate early protein of cytomegalovirus in renal transplant recipients. J Med Virol. 34(4):280-283.